Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRECISE study of synovial biomarkers and ixekizumab response in refractory psoriatic arthritis
2025-521259-21-00Phase 4Authorised
- Sponsor
- Azienda Ospedaliero-Universitaria di Ferrara
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ixekizumab in psoriatic arthritis (PsA), sponsored by Azienda Ospedaliero-Universitaria di Ferrara. Primary endpoints: ACR20 response at T12 and Predictive performance of synovial biomarker test at T12. Planned start Jul 2025; status: authorised.
02
Drugs
ixekizumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2025-521259-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521259-21-00.